China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts.
More info..

CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the 'NMPA'), pursuant to which, the supplemental application to expand the age range of applicable population of the Company's Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the 'MCV4', trade name: Menhycia (R)) from 'children aged from 3 months to 3 years old (47 months)' to 'children aged from 3 months to 6 years old (83 months)' has been approved by NMPA.
More info..

In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum.
More info..

CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, 'CanSinoBIO' or the 'Company'), a leading player in China's vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities.
More info..

CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio.
More info..

CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced.
More info..

On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province.
More info..

In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident.
More info..